Substituted Tetracycline Compounds: A Detailed Analysis of US Patent 8,318,706
Introduction
The United States Patent 8,318,706, issued on November 27, 2012, pertains to novel substituted tetracycline compounds developed by Paratek Pharmaceuticals, Inc. This patent is significant in the field of pharmaceuticals, particularly for the treatment of various bacterial infections and other tetracycline-responsive conditions.
Inventors and Assignee
The patent was invented by a team of researchers including Haregewein Assefa, Laura Honeyman, and Oak Kim, among others, and is assigned to Paratek Pharmaceuticals, Inc., a company based in Boston, MA[5].
Scope of the Patent
Overview of Substituted Tetracycline Compounds
The patent describes a class of novel substituted tetracycline compounds that can be used to treat a wide range of conditions, including bacterial infections and neoplasms. These compounds are derivatives of the tetracycline antibiotic family, which have been modified to enhance their therapeutic efficacy and reduce side effects[1][5].
Therapeutic Applications
The substituted tetracycline compounds covered by this patent are designed to address various tetracycline-responsive states. These include:
- Bacterial Infections: The compounds are effective against a broad spectrum of bacterial infections, making them valuable in the treatment of diseases caused by bacteria.
- Neoplasms: The patent also suggests the potential use of these compounds in treating certain types of cancer, highlighting their versatility in therapeutic applications[1].
Claims of the Patent
Chemical Structure
The patent claims detail the specific chemical structures of the substituted tetracycline compounds. These include various modifications such as the presence of hydrogen, alkyl, alkoxy, alkynyl, alkenyl, aryl, and other functional groups. The claims specify the exact configurations and substitutions that define these novel compounds[1].
Pharmaceutical Compositions
The patent includes claims for pharmaceutical compositions that contain these substituted tetracycline compounds. These compositions can be formulated in various forms, such as tablets, capsules, or other drug delivery systems, and may include additional ingredients like excipients and stabilizers[1].
Methods of Treatment
The patent also covers methods of treating diseases using these substituted tetracycline compounds. This includes specific dosages, administration routes, and treatment regimens for various conditions[1].
Patent Landscape
Related Patents
The patent landscape surrounding US 8,318,706 includes several related patents, particularly those also assigned to Paratek Pharmaceuticals, Inc. For example:
- US 8,513,223: This patent, issued on August 20, 2013, pertains to the use of substituted tetracycline compounds for the treatment of inflammatory skin disorders such as acne and rosacea. It shares some inventors and the same assignee as US 8,318,706[2][5].
Patent Expiration Dates
The patent US 8,318,706 is set to expire on May 1, 2031. This expiration date is crucial for understanding the timeline during which the patent holders have exclusive rights to manufacture and market these compounds[5].
Generic Availability
As of the current date, there is no generic version of the drugs covered by this patent available in the United States. This means that Paratek Pharmaceuticals, Inc. retains exclusive rights to these compounds until the patent expires[5].
Impact on Pharmaceutical Industry
Innovation and Research
The issuance of this patent reflects ongoing innovation in the pharmaceutical industry, particularly in the development of antibiotics and other therapeutic agents. It encourages further research into modifying existing compounds to improve their efficacy and safety profiles.
Market Dominance
Paratek Pharmaceuticals, Inc. holds a significant position in the market for tetracycline-based treatments due to the exclusive rights granted by this patent. This dominance can influence market dynamics, pricing, and the availability of these drugs.
Legal and Regulatory Aspects
Patent Scope and Quality
The scope of this patent, like many others, is subject to scrutiny regarding its breadth and clarity. Research has shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process, which can impact the patent's validity and enforcement[3].
Examination Process
The examination process for this patent would have involved a thorough review of the claims to ensure they meet the criteria for patentability, including novelty, non-obviousness, and utility. Any changes during the examination process would have narrowed the scope of the patent claims to ensure they are specific and enforceable[3].
Conclusion
US Patent 8,318,706 represents a significant advancement in the development of substituted tetracycline compounds for various therapeutic applications. The patent's scope, claims, and expiration date are critical factors in understanding its impact on the pharmaceutical industry and the broader healthcare landscape.
Key Takeaways
- Novel Compounds: The patent covers novel substituted tetracycline compounds with enhanced therapeutic efficacy.
- Therapeutic Applications: These compounds are used to treat bacterial infections and neoplasms.
- Chemical Structure: Specific chemical structures and modifications are detailed in the patent claims.
- Pharmaceutical Compositions: The patent includes claims for various pharmaceutical compositions.
- Methods of Treatment: Specific treatment methods and dosages are covered.
- Related Patents: Other patents, such as US 8,513,223, are related and share similar inventors and assignees.
- Patent Expiration: The patent expires on May 1, 2031.
- Generic Availability: No generic version is currently available.
FAQs
What are the main therapeutic applications of the substituted tetracycline compounds covered by US 8,318,706?
The main therapeutic applications include the treatment of bacterial infections and neoplasms.
Who are the inventors and assignee of US 8,318,706?
The inventors include Haregewein Assefa, Laura Honeyman, and Oak Kim, among others, and the assignee is Paratek Pharmaceuticals, Inc.
What is the expiration date of US 8,318,706?
The patent is set to expire on May 1, 2031.
Are there any related patents to US 8,318,706?
Yes, there are related patents such as US 8,513,223, which covers the use of substituted tetracycline compounds for treating inflammatory skin disorders.
Is a generic version of the drugs covered by this patent available?
No, there is currently no generic version available in the United States.
How does the patent landscape impact the pharmaceutical industry?
The patent landscape influences market dynamics, encourages innovation, and affects the availability and pricing of these drugs.
Sources
- US8318706B2 - Substituted tetracycline compounds - Google Patents
- United States Patent - googleapis.com
- Patent Claims and Patent Scope - Hoover Institution
- Sarecycline: Uses, Interactions, Mechanism of Action - DrugBank
- Generic Seysara Availability - Drugs.com
